| Uncovering a Genetic Polymorphism Located in Huntingtin Associated Protein 1 in Modulation of Central Pain Sensitization Signaling Pathways | Frontiers in neuroscience |  | | 2022 | 426 | 324 |
|
| Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity | British journal of pharmacology | | | 2021 | 339 | 335 |
|
| Exploration du rôle de la modulation GABAergique dans la transmission de la douleur chez l'homme : Effet du modulateur allostérique GABAA N-desméthylclobazam sur la sensibilisation centrale; étude pharmacodynamique et pharmacocinétique chez le volontaire sain | | | | 2021 | 376 | 17 |
|
| GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the α2-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteers | European Journal of Pain |  | | 2020 | 272 | 1 |
|
| Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial | Clinical Microbiology and Infection | | | 2020 | 341 | 267 |
|
| Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions | Clinical Pharmacology and Therapeutics | | | 2017 | 505 | 5 |
|
| The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia | Neuropharmacology | | | 2016 | 608 | 367 |
|
| Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report | The New England journal of medicine | | | 2016 | 945 | 318 |
|
| A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients | Multiple sclerosis | | | 2015 | 658 | 1 |
|
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Lancet. Infectious diseases | | | 2015 | 717 | 0 |
|
| P-glycoprotein: a clue to vitamin K antagonist stabilization | Pharmacogenomics | | | 2015 | 714 | 0 |
|
| A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up | Journal of neuroimmunology | | | 2015 | 613 | 1 |
|
| GABAergic modulation in central sensitization in humans: a randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers | Pain | | | 2015 | 637 | 3 |
|
| Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial | Pain physician | | | 2013 | 638 | 1,173 |
|
| Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment | Pharmacogenomics | | | 2013 | 702 | 0 |
|
